Malcolm Salter, Director at C4 Therapeutics, Inc. (CCCC), sold 755 shares at $30.25 ($23K) on 2021-12-17, disclosed to the SEC on 2021-12-17.
Scheduled sale ($23k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| CCCC | SELL | 2021-09-21 | $38K | — | Filing → |
| CCCC | SELL | 2021-08-24 | $31K | — | Filing → |
| CCCC | SELL | 2021-07-19 | $28K | — | Filing → |